Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(10):1661–1668. doi: 10.1038/bjc.1998.273

Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up.

F A Mauri 1, O Caffo 1, S Veronese 1, P Verderio 1, P Boracchi 1, M Bonzanini 1, N Rossi 1, G Perrone 1, P Dalla Palma 1, M Barbareschi 1
PMCID: PMC2150051  PMID: 9635845

Abstract

Carcinoembryonic antigen (CEA) is a well-known tumour marker whose immunohistochemical expression could be prognostically relevant in breast carcinomas. We evaluated CEA immunohistochemical expression, using the specific T84.66 monoclonal antibody, in a series of 252 consecutive cases of infiltrating breast carcinomas (104 N0, 148 N1/2) with median follow-up of 84 months. Oestrogen receptor (ER) status has been evaluated with the immunohistochemical method (ER1D5 antibody, 10% cut-off value): 121 cases were ER negative, 128 cases were ER positive and in three cases ER status was unknown. CEA staining was cytoplasmic; staining intensity and percentage of reacting cells were combined to obtain a final score (CEA score). The difference between the distribution of CEA score within the modalities of the other variables was not statistically significant. Univariate survival analysis has been performed on the series of node-negative and node-positive patients. In the latter subgroup, this has been performed separately for patients treated with systemic adjuvant hormonal therapy or chemotherapy. A multivariate analysis was only performed for node-positive patients treated with adjuvant therapy. CEA immunoreactivity was not prognostically relevant in any subset of analysed patients. The most important prognostic markers were nodal status and tumour size.

Full text

PDF
1661

Images in this article

1663Figure 1
on p.1663

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Durrleman S., Simon R. Flexible regression models with cubic splines. Stat Med. 1989 May;8(5):551–561. doi: 10.1002/sim.4780080504. [DOI] [PubMed] [Google Scholar]
  2. Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403–410. doi: 10.1111/j.1365-2559.1991.tb00229.x. [DOI] [PubMed] [Google Scholar]
  3. Eskelinen M., Lipponen P., Syrjänen K. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival. Anticancer Res. 1992 Jan-Feb;12(1):91–95. [PubMed] [Google Scholar]
  4. Esteban J. M., Felder B., Ahn C., Simpson J. F., Battifora H., Shively J. E. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer. 1994 Sep 1;74(5):1575–1583. doi: 10.1002/1097-0142(19940901)74:5<1575::aid-cncr2820740513>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  5. Esteban J. M., Paxton R., Mehta P., Battifora H., Shively J. E. Sensitivity and specificity of Gold types 1 to 5 anti-carcinoembryonic antigen monoclonal antibodies: immunohistologic characterization in colorectal cancer and normal tissues. Hum Pathol. 1993 Mar;24(3):322–328. doi: 10.1016/0046-8177(93)90044-h. [DOI] [PubMed] [Google Scholar]
  6. Gion M., Mione R., Dittadi R., Fasan S., Pallini A., Bruscagnin G. Carcinoembryonic antigen, ferritin, and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma. Cancer. 1986 Mar 1;57(5):917–922. doi: 10.1002/1097-0142(19860301)57:5<917::aid-cncr2820570506>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  7. Harrell F. E., Jr, Califf R. M., Pryor D. B., Lee K. L., Rosati R. A. Evaluating the yield of medical tests. JAMA. 1982 May 14;247(18):2543–2546. [PubMed] [Google Scholar]
  8. Hayes D. F., Bast R. C., Desch C. E., Fritsche H., Jr, Kemeny N. E., Jessup J. M., Locker G. Y., Macdonald J. S., Mennel R. G., Norton L. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996 Oct 16;88(20):1456–1466. doi: 10.1093/jnci/88.20.1456. [DOI] [PubMed] [Google Scholar]
  9. Kuhajda F. P., Offutt L. E., Mendelsohn G. The distribution of carcinoembryonic antigen in breast carcinoma. Diagnostic and prognostic implications. Cancer. 1983 Oct 1;52(7):1257–1264. doi: 10.1002/1097-0142(19831001)52:7<1257::aid-cncr2820520721>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  10. Levesque M. A., Diamandis E. P., Yu H., Sutherland D. J. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Res Treat. 1994;30(2):179–195. doi: 10.1007/BF00666062. [DOI] [PubMed] [Google Scholar]
  11. Mansour E. G., Hastert M., Park C. H., Koehler K. A., Petrelli M. Tissue and plasma carcinoembryonic antigen in early breast cancer. A prognostic factor. Cancer. 1983 Apr 1;51(7):1243–1248. doi: 10.1002/1097-0142(19830401)51:7<1243::aid-cncr2820510712>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  12. Molina R., Zanón G., Filella X., Moreno F., Jo J., Daniels M., Latre M. L., Giménez N., Pahisa J., Velasco M. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36(1):41–48. doi: 10.1007/BF00690183. [DOI] [PubMed] [Google Scholar]
  13. Neumaier M., Shively L., Chen F. S., Gaida F. J., Ilgen C., Paxton R. J., Shively J. E., Riggs A. D. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. Cancer Res. 1990 Apr 1;50(7):2128–2134. [PubMed] [Google Scholar]
  14. Sundblad A. S., Pellicer E. M., Ricci L. Carcinoembryonic antigen expression in stages I and II breast cancer: its relationship with clinicopathologic factors. Hum Pathol. 1996 Mar;27(3):297–301. doi: 10.1016/s0046-8177(96)90072-6. [DOI] [PubMed] [Google Scholar]
  15. Todd J. H., Dowle C., Williams M. R., Elston C. W., Ellis I. O., Hinton C. P., Blamey R. W., Haybittle J. L. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987 Oct;56(4):489–492. doi: 10.1038/bjc.1987.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Walker R. A. Demonstration of carcinoembryonic antigen in human breast carcinomas by the immunoperoxidase technique. J Clin Pathol. 1980 Apr;33(4):356–360. doi: 10.1136/jcp.33.4.356. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES